Known targets — ChEMBL curated mechanism
ADRB1CDK4CDK6CHRM2CHRM3DPP4DRD2DRD3DRD4EGFRHRH1HTR1BHTR1DHTR1FHTR2AHTR2CHTR4SLC6A2SLC6A4
The experimentally established mechanism targets of Succinic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 6/20 | 0.57 |
| ▸ | CTSS | P25774 | 3/20 | 0.57 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CTSL | P07711 | 2/20 | 0.46 |
| ▸ | CTSB | P07858 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | SDCBP | O00560 | 1/20 | 0.45 |
| ▸ | SDC2 | P34741 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | PREP | P48147 | 1/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.43 |
| ▸ | APP | P05067 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Succinic Acid SCHEMBL28195154 | 1.00 | CTSK (0.57) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL29674710 | 0.91 | CTSK (0.61) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL59323 | 0.91 | CTSK (0.61) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL256794 | 0.91 | CTSK (0.61) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL467994 | 0.91 | CTSK (0.61) | CTSKCTSSCA1CA2CA7 | |
| Fluoride SCHEMBL7360444 | 0.90 | CTSK (0.59) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL28058549 | 0.90 | CTSK (0.59) | CTSKCTSSCA1CA2CA7 | |
| Fluoride SCHEMBL7360449 | 0.90 | CTSK (0.59) | CTSKCTSSCA1CA2CA7 | |
| Ammonia Solution, Strong SCHEMBL28313812 | 0.90 | CTSK (0.59) | CTSKCTSSCA1CA2CA7 | |
| Glutamic Acid SCHEMBL10275101 | 0.87 | CTSK (0.49) | CTSKCTSSCA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260091024-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BIOHAVEN THERAPEUTICS LTD (US) | 2026-04-02 | — | — | US | disclosed |
| US-20260041673-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BIOHAVEN THERAPEUTICS LTD (US) | 2026-02-12 | — | — | US | disclosed |
| US-12472165-B2 | Riluzole prodrugs and their use | BIOHAVEN THERAPEUTICS LTD. (VG) | 2025-11-18 | — | — | US | disclosed |
| US-20250332148-A1 | RILUZOLE PRODRUGS AND THEIR USE | BIOHAVEN THERAPEUTICS LTD (US) | 2025-10-30 | — | — | US | disclosed |
| US-12295942-B2 | Riluzole prodrugs and their use | BIOHAVEN THERAPEUTICS LTD. (VG) | 2025-05-13 | — | — | US | disclosed |
| US-12213965-B2 | Riluzole prodrugs and their use | BIOHAVEN THERAPEUTICS LTD. (VG) | 2025-02-04 | — | — | US | disclosed |
| US-12005047-B2 | Riluzole prodrugs and their use | BIOHAVEN THERAPEUTICS LTD. (US) | 2024-06-11 | — | — | US | disclosed |
| US-12005046-B2 | Riluzole prodrugs and their use | BIOHAVEN THERAPEUTICS LTD. (US) | 2024-06-11 | — | — | US | disclosed |
| US-20240091205-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2024-03-21 | — | — | US | disclosed |
| US-11911369-B2 | Prodrugs of riluzole and their method of use | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-02-27 | — | — | US | disclosed |
| US-20230381150-A1 | RILUZOLE PRODRUGS AND THEIR USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2023-11-30 | — | — | US | disclosed |
| US-20230017637-A1 | RILUZOLE PRODRUGS AND THEIR USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2023-01-19 | — | — | US | disclosed |
| US-20220396555-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BIOHAVEN THERAPEUTICS LTD. (US) | 2022-12-15 | — | — | US | disclosed |
| EP-4011870-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING RILUZOLE PRODRUGS | Biohaven Pharmaceutical Holding Company Ltd. (US) | 2022-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230381150-A1 | RILUZOLE PRODRUGS AND THEIR USE | APEH, ALDH1A2, UGT1A9 | CTSK 586/4885CTSS 653/4885CA1 1809/4885 |
| US-20260091024-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | IL6ST, GFRA3, GFRA1 | CTSK 1499/4885CTSS 1265/4885CA1 1048/4885 |
| US-12005046-B2 | Riluzole prodrugs and their use | APEH, ALDH1A2, UGT1A9 | CTSK 586/4885CTSS 653/4885CA1 1809/4885 |
| US-11911369-B2 | Prodrugs of riluzole and their method of use | APEH, UGT1A9, ALDH3A1 | CTSK 543/4885CTSS 503/4885CA1 1703/4885 |
| US-12005047-B2 | Riluzole prodrugs and their use | APEH, ALDH1A2, UGT1A9 | CTSK 586/4885CTSS 653/4885CA1 1809/4885 |
| US-20230017637-A1 | RILUZOLE PRODRUGS AND THEIR USE | APEH, ALDH1A2, UGT1A9 | CTSK 586/4885CTSS 653/4885CA1 1809/4885 |
| US-20260041673-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | GFRA3, IL6ST, GFRA1 | CTSK 1659/4885CTSS 1454/4885CA1 1132/4885 |
| US-12472165-B2 | Riluzole prodrugs and their use | APEH, ALDH1A2, UGT1A9 | CTSK 586/4885CTSS 653/4885CA1 1809/4885 |
| US-12295942-B2 | Riluzole prodrugs and their use | APEH, ALDH1A2, UGT1A9 | CTSK 586/4885CTSS 653/4885CA1 1809/4885 |
| US-20240091205-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | APEH, UGT1A9, ALDH3A1 | CTSK 543/4885CTSS 503/4885CA1 1703/4885 |
| US-20250332148-A1 | RILUZOLE PRODRUGS AND THEIR USE | APEH, ALDH1A2, UGT1A9 | CTSK 586/4885CTSS 653/4885CA1 1809/4885 |
| US-12213965-B2 | Riluzole prodrugs and their use | APEH, ALDH1A2, UGT1A9 | CTSK 586/4885CTSS 653/4885CA1 1809/4885 |
| US-20220396555-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | APEH, UGT1A9, ALDH3A1 | CTSK 543/4885CTSS 503/4885CA1 1703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.